Shared on 04 Nov 25
Fair value Increased 1.55%Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.
Shared on 23 Aug 25
Fair value Increased 6.63%The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
Shared on 23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 3.09%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Decreased 0.64%AnalystConsensusTarget has increased revenue growth from 11.5% to 12.7% and decreased profit margin from 23.6% to 19.8%.